特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

子宮頸癌診断検査の世界市場:医療機器のパイプライン評価

Cervical Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2019

発行 GlobalData 商品コード 366601
出版日 ページ情報 英文 113 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.98円で換算しております。
子宮頸癌診断検査の世界市場:医療機器のパイプライン評価 Cervical Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2019
出版日: 2019年11月14日 ページ情報: 英文 113 Pages
概要

当レポートでは、世界の子宮頸癌診断検査の関連製品の市場における、主要なパイプライン製品とその治験の進行状況について調査すると共に、製品の機能・特性の比較分析 (治験の進行段階別) や、主要企業のプロファイルおよび代表的製品、昨今の市場動静 (業績報告・資本取引動向など) といった情報を取りまとめてお届けいたします。

第1章 目次

第2章 イントロダクション

  • 子宮頸癌診断検査の概要

第3章 治験中の製品

  • パイプライン製品:治験段階別
  • パイプライン製品:地域別
  • パイプライン製品:規制経路別
  • パイプライン製品:推定認証時期別
  • パイプライン製品:現在進行中の治験

第4章 治験中のパイプライン製品:企業別

  • 子宮頸癌診断検査の企業:治験段階別のパイプライン製品
  • 子宮頸癌診断検査:治験段階別のパイプライン製品

第5章 子宮頸癌診断検査市場:企業・製品の概要

  • Abbott Diagnostics
    • パイプライン製品および進行中の治験の概要
  • Aindra Systems Pvt. Ltd.
  • Alere Inc.
  • Arbor Vita Corporation
  • Becton, Dickinson and Company
  • BioAffinity Technologies, Inc.
  • BioMark Diagnostics Inc.
  • BioMark Technologies Inc.
  • Cancer Research Technology Limited
  • Cepheid
  • China Sky One Medical, Inc.
  • Cytosystems Ltd
  • Enzo Life Sciences, Inc.
  • Genisphere Inc.
  • Genomic Vision
  • GenomicTree, Inc.
  • Golden Valley Development, Inc.
  • GRANT Life Sciences, Inc.
  • Louisville Bioscience, Inc.
  • MDNA Life Sciences, Inc.
  • MDxHealth SA
  • Milagen, Inc.
  • NeoDiagnostix, Inc.
  • Newcastle University
  • Oncgnostics GmbH
  • ONCOVEDA Cancer Research Center
  • Orion Genomics LLC
  • Precision Biologics, Inc.
  • Preciva Incorporated
  • Roche Diagnostics International Ltd.
  • University of Manchester
  • US Biomarkers, Inc.
  • Vanderbilt University
  • Vigilant Biosciences, Inc.
  • XEPTAGEN SpA

第6章 子宮頸癌診断検査市場:昨今の動向 (全24件)

第7章 付録

図表一覧

図表

List of Tables

  • Table 1: Cervical Cancer Diagnostic Tests - Pipeline Products by Stage of Development 10
  • Table 2: Cervical Cancer Diagnostic Tests - Pipeline Products by Territory 11
  • Table 3: Cervical Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 12
  • Table 4: Cervical Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 13
  • Table 5: Cervical Cancer Diagnostic Tests - Ongoing Clinical Trials 14
  • Table 6: Cervical Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development 15
  • Table 7: Cervical Cancer Diagnostic Tests - Pipeline Products by Stage of Development 16
  • Table 8: Alere Inc Pipeline Products & Ongoing Clinical Trials Overview 17
  • Table 9: NMP179 Test - Product Status 17
  • Table 10: NMP179 Test - Product Description 17
  • Table 11: Augusta University Pipeline Products & Ongoing Clinical Trials Overview 18
  • Table 12: Folate Receptor Biomarker Test - Cervical Cancer Diagnostic Tests - Product Status 18
  • Table 13: Folate Receptor Biomarker Test - Cervical Cancer Diagnostic Tests - Product Description 18
  • Table 14: Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview 19
  • Table 15: BD SurePath Plus Molecular Pap Test System - Product Status 19
  • Table 16: BD SurePath Plus Molecular Pap Test System - Product Description 19
  • Table 17: Biomarker Test - Cervical Cancer Diagnostic Tests - Product Status 20
  • Table 18: Biomarker Test - Cervical Cancer Diagnostic Tests - Product Description 20
  • Table 19: Becton Dickinson and Co - Ongoing Clinical Trials Overview 21
  • Table 20: BD SurePath Plus Molecular Pap Test System - Validation of High Resolution Microendoscope in the Screening of Cervical Cancer Precursor Lesions in Brazil: UH3 - Brazil 22
  • Table 21: Bio Techne Corp Pipeline Products & Ongoing Clinical Trials Overview 23
  • Table 22: RNAscope HPV Assay - Cervical Cancer Diagnostic Tests - Product Status 23
  • Table 23: RNAscope HPV Assay - Cervical Cancer Diagnostic Tests - Product Description 23
  • Table 24: BioAffinity Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 25
  • Table 25: CyPath Diagnostic Assay - Cervical Cancer Diagnostic Tests - Product Status 25
  • Table 26: CyPath Diagnostic Assay - Cervical Cancer Diagnostic Tests - Product Description 25
  • Table 27: BioMark Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 26
  • Table 28: Metabolomics-based Diagnostic Assay - Cervical Cancer Diagnostic Tests - Product Status 26
  • Table 29: Metabolomics-based Diagnostic Assay - Cervical Cancer Diagnostic Tests - Product Description 26
  • Table 30: BioMark Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 28
  • Table 31: Biomarker Assay - Cervical Cancer Diagnostic Tests - Product Status 28
  • Table 32: Biomarker Assay - Cervical Cancer Diagnostic Tests - Product Description 28
  • Table 33: Cepheid Pipeline Products & Ongoing Clinical Trials Overview 29
  • Table 34: Xpert Molecular PAP Assay - Product Status 29
  • Table 35: Xpert Molecular PAP Assay - Product Description 29
  • Table 36: China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 30
  • Table 37: Diagnostic Kit - Carcinoma Cervix - Product Status 30
  • Table 38: Diagnostic Kit - Carcinoma Cervix - Product Description 30
  • Table 39: Cytosystems Ltd Pipeline Products & Ongoing Clinical Trials Overview 31
  • Table 40: Laboratory-Based Diagnostic Test - Cervical Cancer Diagnostic Tests - Product Status 31
  • Table 41: Laboratory-Based Diagnostic Test - Cervical Cancer Diagnostic Tests - Product Description 31
  • Table 42: Enzo Biochem Inc Pipeline Products & Ongoing Clinical Trials Overview 32
  • Table 43: p16 Biomarker - Cervical Cancer Diagnostic Tests - Product Status 32
  • Table 44: p16 Biomarker - Cervical Cancer Diagnostic Tests - Product Description 32
  • Table 45: Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 33
  • Table 46: Liquid Biopsy Test - Cervical Cancer Diagnostic Tests - Product Status 33
  • Table 47: Liquid Biopsy Test - Cervical Cancer Diagnostic Tests - Product Description 33
  • Table 48: GenomicTree Inc Pipeline Products & Ongoing Clinical Trials Overview 35
  • Table 49: EarlyTect Cervical Cancer Diagnostic Tests - Product Status 35
  • Table 50: EarlyTect Cervical Cancer Diagnostic Tests - Product Description 35
  • Table 51: Screening Test - Cervical Cancer Diagnostic Tests - Product Status 36
  • Table 52: Screening Test - Cervical Cancer Diagnostic Tests - Product Description 36
  • Table 53: GRANT Life Sciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview 37
  • Table 54: Serum-Based Test - Cervical Cancer Diagnostic Tests - Product Status 37
  • Table 55: Serum-Based Test - Cervical Cancer Diagnostic Tests - Product Description 37
  • Table 56: HLL Lifecare Ltd Pipeline Products & Ongoing Clinical Trials Overview 38
  • Table 57: Diagnostic ELISA - Cervical Cancer Diagnostic Tests - Product Status 38
  • Table 58: Diagnostic ELISA - Cervical Cancer Diagnostic Tests - Product Description 38
  • Table 59: Louisville Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview 39
  • Table 60: Cervical Cancer Remission pT Test - Product Status 39

List of Figures

  • Figure 1: Cervical Cancer Diagnostic Tests - Pipeline Products by Stage of Development 8
  • Figure 2: Cervical Cancer Diagnostic Tests - Pipeline Products by Territory 9
  • Figure 3: Cervical Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 10
  • Figure 4: Cervical Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 11
  • Figure 5: Cervical Cancer Diagnostic Tests - Ongoing Clinical Trials 12
目次
Product Code: GDME0813EPD

GlobalData's Medical Devices sector report, "Cervical Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2019" provides an overview of Cervical Cancer Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Cervical Cancer Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Cervical Cancer Diagnostic Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Cervical Cancer Diagnostic Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Cervical Cancer Diagnostic Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

  • 1.1 List of Tables 5
  • 1.2 List of Figures 6

2 Introduction 7

  • 2.1 Cervical Cancer Diagnostic Tests Overview 7

3 Products under Development 8

  • 3.1 Cervical Cancer Diagnostic Tests - Pipeline Products by Stage of Development 8
  • 3.2 Cervical Cancer Diagnostic Tests - Pipeline Products by Territory 9
  • 3.3 Cervical Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 10
  • 3.4 Cervical Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 11
  • 3.5 Cervical Cancer Diagnostic Tests - Ongoing Clinical Trials 12

4 Cervical Cancer Diagnostic Tests - Pipeline Products under Development by Companies 13

  • 4.1 Cervical Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development 13
  • 4.2 Cervical Cancer Diagnostic Tests - Pipeline Products by Stage of Development 14

5 Cervical Cancer Diagnostic Tests Companies and Product Overview 15

  • 5.1 Alere Inc Company Overview 15
    • 5.1.1 Alere Inc Pipeline Products & Ongoing Clinical Trials Overview 15
  • 5.2 Augusta University Company Overview 16
    • 5.2.1 Augusta University Pipeline Products & Ongoing Clinical Trials Overview 16
  • 5.3 Becton Dickinson and Co Company Overview 17
    • 5.3.1 Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview 17
  • 5.4 Bio Techne Corp Company Overview 21
    • 5.4.1 Bio Techne Corp Pipeline Products & Ongoing Clinical Trials Overview 21
  • 5.5 BioAffinity Technologies, Inc. Company Overview 22
    • 5.5.1 BioAffinity Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 22
  • 5.6 BioMark Diagnostics Inc Company Overview 23
    • 5.6.1 BioMark Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 23
  • 5.7 BioMark Technologies Inc Company Overview 24
    • 5.7.1 BioMark Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 24
  • 5.8 Cepheid Company Overview 25
    • 5.8.1 Cepheid Pipeline Products & Ongoing Clinical Trials Overview 25
  • 5.9 China Sky One Medical Inc Company Overview 26
    • 5.9.1 China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 26
  • 5.10 Cytosystems Ltd Company Overview 27
    • 5.10.1 Cytosystems Ltd Pipeline Products & Ongoing Clinical Trials Overview 27
  • 5.11 Enzo Biochem Inc Company Overview 28
    • 5.11.1 Enzo Biochem Inc Pipeline Products & Ongoing Clinical Trials Overview 28
  • 5.12 Exact Sciences Corp Company Overview 29
    • 5.12.1 Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 29
  • 5.13 GenomicTree Inc Company Overview 30
    • 5.13.1 GenomicTree Inc Pipeline Products & Ongoing Clinical Trials Overview 30
  • 5.14 GRANT Life Sciences, Inc. Company Overview 32
    • 5.14.1 GRANT Life Sciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview 32
  • 5.15 HLL Lifecare Ltd Company Overview 33
    • 5.15.1 HLL Lifecare Ltd Pipeline Products & Ongoing Clinical Trials Overview 33
  • 5.16 Louisville Bioscience, Inc. Company Overview 34
    • 5.16.1 Louisville Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview 34
  • 5.17 MDNA Life Sciences Inc Company Overview 35
    • 5.17.1 MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 35
  • 5.18 MDxHealth SA Company Overview 36
    • 5.18.1 MDxHealth SA Pipeline Products & Ongoing Clinical Trials Overview 36
  • 5.19 Milagen Inc Company Overview 37
    • 5.19.1 Milagen Inc Pipeline Products & Ongoing Clinical Trials Overview 37
  • 5.20 Olympia Diagnostics Inc Company Overview 38
    • 5.20.1 Olympia Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 38
  • 5.21 Oncgnostics GmbH Company Overview 40
    • 5.21.1 Oncgnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview 40
  • 5.22 ONCOVEDA Cancer Research Center Company Overview 41
    • 5.22.1 ONCOVEDA Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 41
  • 5.23 Precision Biologics Inc Company Overview 42
    • 5.23.1 Precision Biologics Inc Pipeline Products & Ongoing Clinical Trials Overview 42
  • 5.24 US Biomarkers Inc Company Overview 43
    • 5.24.1 US Biomarkers Inc Pipeline Products & Ongoing Clinical Trials Overview 43
  • 5.25 XEPTAGEN SpA Company Overview 44
    • 5.25.1 XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview 44

6 Cervical Cancer Diagnostic Tests - Recent Developments 45

  • 6.1 Nov 05, 2019: BD announces results for 2019 fourth fiscal quarter and full year; provides fiscal 2020 guidance 45
  • 6.2 Oct 30, 2019: Genomic Vision: Financial information for the third quarter of 2019 46
  • 6.3 Oct 23, 2019: AdvaMed Statement on BD Sterilization Plant in Georgia 47
  • 6.4 Oct 22, 2019: Quest Diagnostics reports third quarter 2019 financial results 48
  • 6.5 Oct 03, 2019: Genomic Vision and PolyAn sign an agreement for the production and supply of Coverslips 48
  • 6.6 Sep 26, 2019: BD announces leadership succession plan 49
  • 6.7 Sep 24, 2019: Genomic Vision: First-half 2019 results 50
  • 6.8 Sep 10, 2019: Quest Diagnostics names Manuel O. Mendez as new commercial leader 53
  • 6.9 Aug 29, 2019: MDxHealth reports half year 2019 financial results and strategic update 54
  • 6.10 Aug 26, 2019: New technique isolates placental cells for non-invasive genetic testing 56
  • 6.11 Aug 20, 2019: Cancer Genetics reports second quarter 2019 financial results and provides strategic business update 57
  • 6.12 Aug 06, 2019: BD announces results for 2019 third fiscal quarter; reaffirms fiscal 2019 guidance 58

7 Appendix 110

  • 7.1 Methodology 110
  • 7.2 About GlobalData 113
  • 7.3 Contact Us 113
  • 7.4 Disclaimer 113